What is Dianthus Therapeutics's D&A?

Dianthus Therapeutics (DNTH) reported D&A of $32K in Q1 2026.

How has Dianthus Therapeutics's D&A changed year-over-year?

Dianthus Therapeutics's D&A increased by 18.5% year-over-year, from $27K to $32K.

What is the long-term trend for Dianthus Therapeutics's D&A?

Over 3 years (2021 to 2024), Dianthus Therapeutics's D&A has grown at a -63.8% compound annual growth rate (CAGR), from $2.02M to $96K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Dianthus Therapeutics DNTH D&A

D&A at other companies

Johnson & JohnsonJNJ

$2B+13.1%

AmgenAMGN

$1.12B-19.5%

Kymera TherapeuticsKYMR

$2.02M-1.3%

Protagonist TherapeuticsPTGX

$407K+70.3%

TG TherapeuticsTGTX

$32K+300%

Immunovant, Inc.IMVT

$96K-11.9%

Other financials

Income statement

See full

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Balance sheet

See full

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Cash flow

See full

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Valuation

See full

Market cap$4.51B+662%

Profitability

See full

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Returns & leverage

See full

Return on equity-28.6%+3.2pp

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dianthus Therapeutics's D&A?: Dianthus Therapeutics (DNTH) reported D&A of $32K in Q1 2026.
How has Dianthus Therapeutics's D&A changed year-over-year?: Dianthus Therapeutics's D&A increased by 18.5% year-over-year, from $27K to $32K.
What is the long-term trend for Dianthus Therapeutics's D&A?: Over 3 years (2021 to 2024), Dianthus Therapeutics's D&A has grown at a -63.8% compound annual growth rate (CAGR), from $2.02M to $96K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.